Analysts Offer Predictions for AUPH FY2026 Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the biotechnology company will earn $0.64 per share for the year. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share.

Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Trading Down 0.6%

Shares of Aurinia Pharmaceuticals stock traded down $0.05 on Tuesday, hitting $8.18. 942,470 shares of the company traded hands, compared to its average volume of 1,335,987. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.11 billion, a PE ratio of -54.53 and a beta of 1.15. The stock's 50 day moving average price is $7.97 and its 200-day moving average price is $8.25. Aurinia Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. grew its stake in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 6,174 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $135,000. Union Bancaire Privee UBP SA purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $108,000. IFP Advisors Inc raised its stake in shares of Aurinia Pharmaceuticals by 31.0% during the 4th quarter. IFP Advisors Inc now owns 271,132 shares of the biotechnology company's stock worth $2,435,000 after acquiring an additional 64,107 shares in the last quarter. Finally, US Bancorp DE lifted its position in Aurinia Pharmaceuticals by 61.9% during the fourth quarter. US Bancorp DE now owns 19,366 shares of the biotechnology company's stock valued at $174,000 after acquiring an additional 7,406 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.